Table 1 The baseline characteristics of studied groups

Gender, n (%)

0.869^c

 Male

67 (73.6 %)

30 (75 %)

 Female

24 (26.4 %)

10 (25 %)

Age (years, mean ± SD) (range)

66.3 ± 9.4 (43–90)

66.9 ± 8.6 (47–84)

0.700^d

Location of cancer, n (%)

0.195^c

 Proximal third

15 (16.5 %)

3 (7.5 %)

 Middle third

66 (72.5 %)

29 (72.5 %)

 Distal third

10 (11.0 %)

8 (20.0 %)

Complications before stent placement, n (%)

0.601^c

 Yes

41 (46.1 %)

20 (50 %)

 No

50 (55.9 %)

20 (50 %)

Local lymph node enlargement, n (%)^a

0.686^c

 Yes

69 (75.8 %)

29 (72.5 %)

 No

22 (24.2 %)

11 (27.5 %)

Tumor stage, n (%)^b

0.437^c

 III

61 (67.0 %)

24 (60.0 %)

 IV

30 (33.0 %)

16 (40.0 %)

Time of stent placement (min, mean ± SD) (range)

22.6 ± 4.9 (15–35)

20.2 ± 4.7 (14–32)

0.792^d

Length of tumor (cm, mean ± SD) (range)

5.3 ± 1.3 (3–10)

5.5 ± 1.5 (2.5–8)

0.139^d

Length of stent (cm, mean ± SD) (range)

9.3 ± 2.0 (6–16)

10.5 ± 1.6 (6–14)

0.274^d

Esophagus dilation, n (%)

0.775^c

 Yes

57 (62.6 %)

24 (60 %)

 No

34 (37.4 %)

16 (40 %)